학술논문
A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection
Document Type
Article
Author
Source
In Clinical Microbiology and Infection October 2023 29(10):1320-1327
Subject
Language
ISSN
1198-743X